Eptinezumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Eptinezumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Eptinezumab is a humanised anti-CGRP monoclonal antibody, FDA-approved for the preventive treatment of episodic and chronic migraine in adults (brand name: Vyepti), though it is not currently registered in Australia. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, a brainstem-origin aura subtype of migraine, with 0 registered clinical trials specific to this subtype but 8 publications — including a post-hoc Phase 3 subgroup analysis — currently supporting this direction. This prediction represents a clinically coherent indication extension within the migraine spectrum rather than a novel disease target.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Episodic and chronic migraine prevention (FDA-approved; not TGA-registered in Australia) |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L2 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Proceed with Guardrails |
Why Is This Prediction Reasonable?
Eptinezumab is a humanised IgG1 monoclonal antibody that binds directly to calcitonin gene-related peptide (CGRP), a potent vasodilatory neuropeptide released during migraine attacks. By neutralising circulating CGRP before it can activate its receptor on trigeminal afferents and meningeal vessels, eptinezumab reduces migraine frequency. Its intravenous route of administration provides a pharmacokinetic advantage: therapeutic plasma levels are reached within 30 minutes of infusion, offering faster onset compared to subcutaneous anti-CGRP agents.
Migraine with brainstem aura (formerly termed basilar-type migraine) is characterised by aura symptoms originating from the brainstem — including bilateral tinnitus, diplopia, dysarthria, vertigo, and ataxia — followed by migraine headache. CGRP is released centrally following cortical spreading depression (CSD), activating trigeminal nucleus caudalis neurons in the brainstem. Trigeminal nucleus activation is a recognised downstream step in the brainstem aura cascade, making CGRP blockade mechanistically relevant to this specific subtype. Elevated CGRP levels have been demonstrated during aura attacks in human provocation studies.
The existing Phase 3 evidence base — the PROMISE-1 and PROMISE-2 trials — enrolled patients with episodic and chronic migraine respectively, and included participants who reported aura. A pre-specified post-hoc subgroup analysis (PMID 35302389) demonstrated comparable efficacy and safety of eptinezumab in migraine patients with self-reported aura. Migraine with brainstem aura therefore represents a biologically coherent and clinically plausible aura-subtype extension of the established indication, rather than a wholly novel disease target.
Clinical Trial Evidence
Currently no clinical trials specifically investigating eptinezumab for migraine with brainstem aura are registered (searched ClinicalTrials.gov and ICTRP on 2026-03-09).
Note for clinicians: The pivotal PROMISE-1 (NCT02559895, episodic migraine) and PROMISE-2 (NCT02974153, chronic migraine) Phase 3 trials both enrolled participants with aura, and support the broader aura indication indirectly. No dedicated trial for the brainstem aura subtype has been identified.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35302389 | 2022 | Post-hoc Phase 3 RCT subgroup analysis | Cephalalgia | Eptinezumab demonstrated comparable efficacy and safety for migraine prevention in patients with self-reported aura across pooled PROMISE-1 and PROMISE-2 data; most directly relevant to brainstem aura subtype |
| 35268319 | 2022 | Case series + literature review | J Clin Med | Anti-CGRP monoclonal antibodies including eptinezumab, fremanezumab, and galcanezumab may reduce aura frequency in addition to headache prevention; supports biological plausibility for aura-subtype extension |
| 40341526 | 2025 | Genetic-clinical correlation review | Headache | Two genetic migraine cases (including chronic migraine with visual aura) responding to CGRP antagonist therapy; supports CGRP pathway relevance across migraine aura subtypes |
| 40191903 | 2025 | Case report | Rev Neurol | Successful use of eptinezumab in chronic migraine with aura refractory to two subcutaneous CGRP antibodies; highlights IV route as a clinical advantage when wearing-off occurs |
| 40229719 | 2025 | RCT (mechanism study) | J Headache Pain | PACAP38-induced migraine attacks are independent of CGRP signalling, clarifying that parallel CGRP-independent pathways also contribute; important for understanding non-responders |
| 30725283 | 2019 | Review | Handb Exp Pharmacol | Comprehensive review of CGRP’s role in migraine pathogenesis including aura mechanisms and trigeminal nucleus brainstem involvement; mechanistic foundation for anti-CGRP therapy |
| 32699706 | 2020 | Review | Cureus | Review of CGRP antagonists covering all four approved anti-CGRP preventive agents including eptinezumab; contextualises class efficacy across episodic and chronic migraine |
| 33550872 | 2021 | Review | Pain Management | Overview of new migraine treatment landscape including eptinezumab as a preventive option; covers CGRP pathway pharmacology and neurovascular hypothesis |
Australia Market Information
Eptinezumab is not currently registered on the Australian Register of Therapeutic Goods (ARTG). There are no ARTG entries for this product.
For reference, eptinezumab is commercially available internationally as:
| Market | Brand Name | Dosage Form | Approved Indication |
|---|---|---|---|
| United States (FDA, approved Feb 2020) | Vyepti (eptinezumab-jjmr) | 100 mg/mL solution for IV infusion | Preventive treatment of migraine in adults |
| European Union (EMA, approved Jul 2022) | Vyepti | 100 mg/mL solution for IV infusion | Preventive treatment of migraine in adults |
Australian clinicians seeking access would need to apply through the TGA Special Access Scheme (SAS Category B) or via a sponsored clinical trial. The existing FDA and EMA Phase 3 data package (PROMISE-1 and PROMISE-2) would support a future ARTG registration application.
Safety Considerations
Eptinezumab is not TGA-registered; Australian Product Information is not available. Please refer to the FDA Prescribing Information for Vyepti (eptinezumab-jjmr) for full safety data.
Based on known class effects of anti-CGRP monoclonal antibodies:
- Hypersensitivity reactions: Anaphylaxis and angioedema have been reported with IV eptinezumab. Appropriate monitoring for at least 1 hour post-infusion and availability of resuscitation equipment is recommended.
- Cardiovascular considerations: As CGRP is a physiological vasodilator, long-term blockade in patients with pre-existing ischaemic cardiovascular or cerebrovascular disease warrants caution; class-level safety in these populations has not been fully characterised.
- No drug-drug interactions were identified in the evidence pack query (DDI query status: not found).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Migraine with brainstem aura shares the same fundamental CGRP-driven trigeminal cascade as the FDA-approved indication, and indirect Level 2 evidence from a post-hoc Phase 3 subgroup analysis in patients with aura supports clinical plausibility. However, dedicated prospective data for the brainstem aura subtype is absent, and the drug is not currently accessible in Australia through registered channels.
To proceed, the following is needed:
- Regulatory pathway: Pursue TGA SAS Category B application or evaluate ARTG registration feasibility using the existing FDA/EMA data package
- Clinical evidence gap: Commission or identify a prospective subgroup analysis or dedicated clinical trial specifically enrolling migraine with brainstem aura patients
- Infrastructure assessment: Evaluate readiness of Australian infusion centres for quarterly IV administration (30-minute infusion protocol)
- Safety review: Obtain full FDA Prescribing Information for Vyepti and conduct a formal safety review prior to SAS application, with particular attention to hypersensitivity monitoring protocols
- MOA data completion: Retrieve complete mechanism of action data via DrugBank API (identified as a high-severity data gap in this evidence pack)
- CGRP-independent pathway monitoring: Given emerging data on PACAP38-independent migraine triggers (PMID 40229719), consider monitoring for non-responders in the brainstem aura population
Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application. All prescribing decisions must be made by qualified healthcare professionals in accordance with applicable Australian regulations.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.